Bringing the Oncology Trial to the Patient: New Perspectives and Technologies That Enable More Engaging Trial Participation

The growing use of decentralized clinical trials (DCTs) has enabled greater patient engagement and driven diversity in trials by reducing the need for participants to frequently travel to investigator sites. While the unique needs of oncology trials might have initially made it seem a DCT approach doesn’t apply, there is now a growing consensus that there is a benefit to using a hybrid approach to DCTs, where patients go to investigator sites when absolutely required, but participate remotely for those aspects of the trial where it is feasible to do so.

In this webinar, featured speakers will discuss the incorporation of DCT methodologies into clinical trials including:

• Where do we start? At what point in trial design does the impact of DCTs need to be factored in?
• What remote data collection methodologies and other DCT services are appropriate for oncology, and what are the regulatory implications of using them?
• How can patient diversity and equity be improved through a hybrid DCT approach?
• Special considerations for pediatric trials and those involving elderly participants

Register for this webinar in which a panel of speakers will answer these and other questions to raise awareness and prompt continued development of patient-centric trial designs.

Speakers

(Moderator) Kathleen Griffin, VP, DCT Strategy & Enablement, Labcorp Drug Development

Kathleen has 26 years of experience in life sciences consulting and clinical research organization management, all with a focus on strategy, development and creation of new approaches. She is the founder of a boutique management consulting firm focused in life sciences due diligence, management supplementation, strategy and organizational development. The firm was acquired by a top 5 CRO. Kathleen is passionate about improving experiences for patients and sites and the opportunity to disrupt drug development. She is a problem solver and big picture thinker with a passion for the ability to use data and technology to change the way drug are developed and delivered.

Message Presenter

Melissa Harris, Director, Patient Recruitment & Engagement, Global Patient Engagement, Labcorp Drug Development

Melissa has 21 years of industry experience with three years of Labcorp tenure creating patient-centric recruitment programs for all phases of studies, including pediatric, rare and hard-to-reach patient populations. Melissa works to harness the benefits of applying innovative solutions toward successful patient recruitment campaigns while driving health literacy and patient-led trials to reduce study burden and facilitate the study into everyday life. Melissa also supports Labcorp’s Voice of Patient program to drive patient insights into every step of the drug development paradigm.

Message Presenter

Jennifer Urwongse, MBA, Associate Director, Commercial Strategy, Decentralized Clinical Trials, Labcorp Drug Development

Jennifer Urwongse is an Associate Director at LabCorp Drug Development Inc. She is on the Commercial Strategy team within the Decentralized Clinical Trials (DCT) group, and helps clients understand and develop appropriate DCT strategies for their trials. She focuses on DCT technology and services that engage patients to participate in trials beyond the investigator site. Prior to joining LabCorp in 2009, Jennifer was a management consultant for a life science consulting firm and an investment banker at a major multinational investment bank. Jennifer received a BA in Economics from the University of Virginia and an MBA from the Massachusetts Institute of Technology.

Message Presenter

Begoña de las Heras Garcia, Senior Medical Director, Oncology MedSci, Oncology Global Clinical Development, Labcorp Drug Development

Begoña is a board-certified Medical Oncologist, which she received from the University Autonoma de Madrid in Spain. She has almost 20 years of national and international clinical/clinical research oncology experience in Phases I to III, mainly in solid tumors and in some hematological malignancies, such as lymphoma, myeloma and myelodysplastic syndrome. Begoña has a special interest in early-phase oncology research. She has provided a significant contribution to a great number of INDs, moving drugs from preclinical to first-in-human (FIH), including orphan drug applications and one NDA. She is co-author of 8 book chapters and author/co-author of more than 25 index papers in the oncology field. She has delivered more than 40 presentations in Spanish and at international conferences. Begoña was named as inventor on two patent applications due to her contribution to the clinical trials and is a member of the Spanish Society of Medical Oncology, European Society of Clinical Oncology, American Society of Clinical Oncology and Madrid Medical’s School.

Message Presenter